948 related articles for article (PubMed ID: 24638075)
1. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development.
Ekert JE; Johnson K; Strake B; Pardinas J; Jarantow S; Perkinson R; Colter DC
PLoS One; 2014; 9(3):e92248. PubMed ID: 24638075
[TBL] [Abstract][Full Text] [Related]
2. Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines.
Luca AC; Mersch S; Deenen R; Schmidt S; Messner I; Schäfer KL; Baldus SE; Huckenbeck W; Piekorz RP; Knoefel WT; Krieg A; Stoecklein NH
PLoS One; 2013; 8(3):e59689. PubMed ID: 23555746
[TBL] [Abstract][Full Text] [Related]
3. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
Li Y; Huang X; Zhang J; Li Y; Ma K
Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
6. 3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems.
Howes AL; Richardson RD; Finlay D; Vuori K
PLoS One; 2014; 9(9):e108283. PubMed ID: 25247711
[TBL] [Abstract][Full Text] [Related]
7. Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.
Van Der Steen N; Leonetti A; Keller K; Dekker H; Funel N; Lardon F; Ruijtenbeek R; Tiseo M; Rolfo C; Pauwels P; Peters GJ; Giovannetti E
Biochem Pharmacol; 2019 Aug; 166():128-138. PubMed ID: 31078602
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
9. Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing.
Xu KP; Yu FS
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2242-8. PubMed ID: 17460286
[TBL] [Abstract][Full Text] [Related]
10. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
[TBL] [Abstract][Full Text] [Related]
11. AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies.
Godugu C; Patel AR; Desai U; Andey T; Sams A; Singh M
PLoS One; 2013; 8(1):e53708. PubMed ID: 23349734
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
[TBL] [Abstract][Full Text] [Related]
13. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
Elife; 2020 Sep; 9():. PubMed ID: 32897190
[TBL] [Abstract][Full Text] [Related]
14. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
[TBL] [Abstract][Full Text] [Related]
15. Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation.
Florio A; Johnson S; Salvatori R; Vasmatzis G
Sci Rep; 2024 Mar; 14(1):7303. PubMed ID: 38538642
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
17. Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy.
Serilmez M; Özgür E; Karaman S; Gezer U; Duranyıldız D
Cancer Biomark; 2019; 25(2):177-184. PubMed ID: 31104010
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous 2D and 3D cell culture array for multicellular geometry, drug discovery and tumor microenvironment reconstruction.
Li S; Yang K; Chen X; Zhu X; Zhou H; Li P; Chen Y; Jiang Y; Li T; Qin X; Yang H; Wu C; Ji B; You F; Liu Y
Biofabrication; 2021 Aug; 13(4):. PubMed ID: 34407511
[TBL] [Abstract][Full Text] [Related]
19. Real-time viability and apoptosis kinetic detection method of 3D multicellular tumor spheroids using the Celigo Image Cytometer.
Kessel S; Cribbes S; Bonasu S; Rice W; Qiu J; Chan LL
Cytometry A; 2017 Sep; 91(9):883-892. PubMed ID: 28618188
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Liu B; Chen D; Chen S; Saber A; Haisma H
Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
